Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23608948 | 0.82 | GPR55 (0.47) | CYP19A1NAMPTKDM4EALDH1A1HPGD | |
| SCHEMBL23609271 | 0.77 | KDM4E (0.40) | CYP19A1KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL23608965 | 0.74 | CYP19A1 (0.41) | CYP19A1NAMPTKDM4EALDH1A1LMNA | |
| SCHEMBL30406544 | 0.74 | CYP19A1 (0.40) | CYP19A1NAMPTKDM4EALDH1A1LMNA | |
| SCHEMBL23608959 | 0.73 | SMN1; SMN2 (0.42) | CYP19A1NAMPTKDM4EALDH1A1LMNA | |
| SCHEMBL23609142 | 0.72 | CYP19A1 (0.41) | CYP19A1KDM4EALDH1A1LMNATP53 | |
| SCHEMBL23608978 | 0.72 | SMN1; SMN2 (0.43) | CYP19A1KDM4EALDH1A1LMNAACHE | |
| SCHEMBL23608946 | 0.72 | SMN1; SMN2 (0.41) | CYP19A1NAMPTKDM4ELMNAMAPK1 | |
| SCHEMBL23608962 | 0.71 | IRAK1 (0.39) | KDM4EALDH1A1HPGD | |
| SCHEMBL30406696 | 0.71 | NTRK1 (0.35) | CYP19A1NAMPTKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117592-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2023-04-20 | — | — | US | disclosed |
| WO-2021133689-A2 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117592-A1 | LIPOXYGENASE INHIBITORS | ALOX15B, ALOX12, ALOX5 | CYP19A1 153/4885NAMPT 965/4885KDM4E 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.